ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Bioxytran Inc (QB)

Bioxytran Inc (QB) (BIXT)

0.089
0.00
(0.00%)
Closed July 17 4:00PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
0.089
Bid
0.0889
Ask
0.099
Volume
-
0.00 Day's Range 0.00
0.071 52 Week Range 0.35
Market Cap
Previous Close
0.089
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
87,951
Shares Outstanding
174,962,481
Dividend Yield
-
PE Ratio
-3.67
Earnings Per Share (EPS)
-0.02
Revenue
-
Net Profit
-4.28M

About Bioxytran Inc (QB)

Bioxytran, Inc. is a clinical stage pharmaceutical company focused on the development, manufacture and commercialization of therapeutic drugs designed to address hypoxia in humans, which is a lack of oxygen to tissues. Hypoxia, needs to be addressed quickly, otherwise it results in necrosis, which i... Bioxytran, Inc. is a clinical stage pharmaceutical company focused on the development, manufacture and commercialization of therapeutic drugs designed to address hypoxia in humans, which is a lack of oxygen to tissues. Hypoxia, needs to be addressed quickly, otherwise it results in necrosis, which is the death of cells comprising body tissue. Necrosis cannot be reversed. Our lead drug candidate, code named BXT-25, is an Acellular Oxygen Carrier ("AOC") consisting of bovine hemoglobin stabilized with a co-polymer with an intended application that includes the treatment of hypoxic conditions in the brain resulting from stroke. Our subsidiary, Pharmalectin Inc. is focused on the development, manufacturing and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin has developed a novel method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Our lead drug candidate, named ProLectin-M, is a complex polysaccharide derived from natural sources that binds to, and blocks the activity of galectins. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Reno, Nevada, USA
Founded
1970
Bioxytran Inc (QB) is listed in the Pharmaceutical Preparations sector of the OTCMarkets with ticker BIXT. The last closing price for Bioxytran (QB) was $0.09. Over the last year, Bioxytran (QB) shares have traded in a share price range of $ 0.071 to $ 0.35.

Bioxytran (QB) currently has 174,962,481 shares outstanding. The market capitalization of Bioxytran (QB) is $15.57 million. Bioxytran (QB) has a price to earnings ratio (PE ratio) of -3.67.

BIXT Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.002-2.19780219780.0910.094950.0805239470.08646446CS
4-0.002-2.19780219780.0910.098220.0752909420.08983987CS
12-0.0615-40.86378737540.15050.15250.0752879510.10772118CS
26-0.046-34.07407407410.1350.15250.0752940530.11726744CS
52-0.056-38.62068965520.1450.350.0711080420.1446914CS
1560.088729566.66666670.00031.250.0003794710.28570159CS
260-1.011-91.90909090911.11.40.0001582930.30022949CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ADTXAditxt Inc
$ 2.65
(65.64%)
11.07M
SHIMShimmick Corporation
$ 2.94
(42.03%)
3.84M
SOHOSotherly Hotels Inc
$ 1.78
(40.16%)
31
APVOAptevo Therapeutics Inc
$ 0.4391
(31.07%)
32.01M
ASSTAsset Entities Inc
$ 2.03
(29.30%)
5.13M
ASLNASLAN Pharmaceuticals Ltd
$ 0.5599
(-49.56%)
392.37k
SAVACassava Sciences Inc
$ 9.84
(-27.27%)
1.8M
SSTISoundThinking Inc
$ 11.11
(-23.33%)
21
GRNQGreenpro Capital Corporation
$ 1.13
(-17.52%)
24.59k
PETWag Group Company
$ 1.32
(-14.84%)
68.92k
APVOAptevo Therapeutics Inc
$ 0.4393
(31.13%)
32.01M
VERBVerb Technology Company Inc
$ 0.1343
(15.38%)
30.91M
CEROCERo Therapeutics Holdings Inc
$ 0.1998
(2.46%)
13.36M
NVDANVIDIA Corporation
$ 121.2501
(-4.04%)
13.19M
ADTXAditxt Inc
$ 2.6502
(65.65%)
11.07M

BIXT Discussion

View Posts
show_me_money show_me_money 15 hours ago
We lose our money for now?
👍️0
cashmagnet cashmagnet 2 days ago
That post was from almost one year ago...Is there any article more recent that would clue us in on Bioxytran's current progress? Thanks!
👍️0
Retire43 Retire43 2 days ago
https://bioxytraninc.us4.list-manage.com/track/click?u=3ab1704628c56ed50088fc32b&id=5f88f5d23a&e=6b153bfc39

👍️0
theswordman theswordman 7 days ago
Macchio is correct. From MDX website (notice the vague answers--tricky wording on several items on website??)

Q. WHAT IS THE REGULATORY STATUS OF THE DEVELOPED MEDICAL DEVICE?

A. MDX Life Sciences is capable to provide a FDA approved device that will monitor 4 physiological
parameters from tissues of patients in real time. The TMS will need a special approval by the FDA.
👍️0
Ecomike Ecomike 2 weeks ago
Where do you do your DD dude? The library of the Roman Empire or the Middle ages?|

More Hogwash and fairy tails just like you did on IFUS, before you got schooled and educated by me?
👍️0
Ecomike Ecomike 2 weeks ago
👍️0
Ecomike Ecomike 2 weeks ago
https://www.slideserve.com/cana/avraham-mayevsky
👍️0
Ecomike Ecomike 2 weeks ago
👍️0
Ecomike Ecomike 2 weeks ago
"MDX Viewer as an analytical method, which is an FDA approved device to measure tissue oxygenation. The device measures the consumption of oxygen molecules in tissues on a cellular level.

The output of the MDX Viewer is the Brain Metabolic Score BMS, which is a vital part of the approval process for Bioxytran’s acellular oxygen carrier (AOC) molecule called BXT-25. Bioxytran plans on using the BXT-25 in its clinical trials for ischemic stroke and Alzheimer’s disease patients as a way to replace hyperbaric oxygen treatment (HBOT).

https://www.globenewswire.com/news-release/2024/06/27/2905450/0/en/Bioxytran-s-Advisor-Releases-Book-on-Hyperbaric-Oxygenation-Related-to-Stroke-Alzheimer-s-Patients.html
👍️0
Ecomike Ecomike 2 weeks ago
The device is already FDA Approved:

"The book is directly tied to the Hypoxia platform technology which uses the MDX Viewer as an analytical method, which is an FDA approved device to measure tissue oxygenation. "

You said: He is head of MDX Life Sciences which has developed the MDX Viewer and is seeking FDA approval for the device. You shouldn't spread misinformation.
👍️0
RMacchio RMacchio 2 weeks ago
I read that she won a Nobel prize already
Are you talking about Avraham Mayevsky? The advisor is a "he" not a "she" and "he" didn't win a Nobel prize. He is head of MDX Life Sciences which has developed the MDX Viewer and is seeking FDA approval for the device. You shouldn't spread misinformation.

BTW, David Platt (CEO of BIXT) and Ola Soderquist (CFO of BIXT) are also managers in MDX Life Sciences. You can find info on the company at MDX Life Sciences. The MDX Viewer is being used to validate BXT-25 and neither of these products have FDA approval. I'm not sure how useful the MDX Viewer and associated TMS score are and also am not clear on the relationship between BIXT and MDX Life Sciences. The MDX Viewer and BXT-25 seem to be tightly linked - they might both be revolutionary products or could both end up in the ashbin of history. I hope it is the former.
👍️0
Ecomike Ecomike 2 weeks ago
Nice rally today up 9.65% on slow pre Holiday day
👍️0
Ecomike Ecomike 2 weeks ago
I noticed a 1/2 Million share bid show up this week and the well known naked shorts/MMs backed up in a panic looking for cloths and fresh shelter. It was rather comical.

Reminded me of

👍️0
Ecomike Ecomike 2 weeks ago
You still panhandle bashing for the paychecks at the Hedge fund/Broker dealer, trying to manipulate the stock price for chump change?
👍️0
Ecomike Ecomike 2 weeks ago
Do not forget, I read that she won a Nobel Prize already

$BIXT News June 27, 2024

Bioxytran’s Advisor Releases Book on Hyperbaric Oxygenation Related to Stroke & Alzheimer’s Patients
https://www.globenewswire.com/news-release/2024/06/27/2905450/0/en/Bioxytran-s-Advisor-Releases-Book-on-Hyperbaric-Oxygenation-Related-to-Stroke-Alzheimer-s-Patients.html
👍️0
eqinvestor eqinvestor 2 weeks ago
The CEO has been running around for years telling the same BS story. Ask him how last company did?
👍️0
janga janga 3 weeks ago
If there’s any chance on earth that this medical technology can do anything on that scale even close isn’t it a gift from heaven?
👍️ 1
govprs govprs 3 weeks ago
Nobody noticed.
👍️0
Retire43 Retire43 3 weeks ago
This is very promising and exciting for the company and shareholders

https://www.globenewswire.com/news-release/2024/06/27/2905450/0/en/Bioxytran-s-Advisor-Releases-Book-on-Hyperbaric-Oxygenation-Related-to-Stroke-Alzheimer-s-Patients.html
👍️ 1 💯 1
BlazingStocks BlazingStocks 3 weeks ago
$BIXT News June 27, 2024

Bioxytran’s Advisor Releases Book on Hyperbaric Oxygenation Related to Stroke & Alzheimer’s Patients
https://www.globenewswire.com/news-release/2024/06/27/2905450/0/en/Bioxytran-s-Advisor-Releases-Book-on-Hyperbaric-Oxygenation-Related-to-Stroke-Alzheimer-s-Patients.html
👍️ 1
luckyapp luckyapp 4 weeks ago
do you not have anything better to do then try and bad mouth ecomike all over ihub.
I have made more money thanks to ecomike then from anyone else.
👍️ 1 💥 1 💯 1 😍 1 🚀 1
RMacchio RMacchio 4 weeks ago
So much potential and so little progress. They have been talking about performing a dosing study for over a year now and still don't seem to have started. And the dosing study is required before they can even begin Phase III testing. What the heck is going on? They set up their Indian subsidiary at the end of 2022 for commercialization and they still seem to be sitting on their hands, waiting for what?

The latest news is painting a bleak picture for the future of COVID... experts predict that, with repeated COVID infections, everyone will eventually be suffering from long COVID. BIXT has a solution but doesn't seem to feel any urgency.
👍️0
govprs govprs 1 month ago
Sounds like a dud. PPS remains depressed
👍️ 1 💯 1
Ecomike Ecomike 1 month ago
**BIXT Live chat starts in 15 minutes**

MIAMI , June 12, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 72nd Emerging Growth Conference on June 12 & 13, 2024.
The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.
Register for the Conference here.
https://goto.webcasts.com/starthere.jsp?ei=1658205&tp_key=76d4029138&sti=globe
Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com

**BIXT is at 1:10 PM today (I think EST zone since the conference firm is in Florida?)**
💩 1 🤡 1
Ecomike Ecomike 1 month ago
What would you like to know about BIXT?
💩 1 🤡 1
Riverman1859 Riverman1859 1 month ago
Just read an article about this : anybody have any real
Insight about the actual company ?
👍️0
Riverman1859 Riverman1859 1 month ago
Just read an article about this : anybody have any real
Insight about the actual company ?
👍️0
tripmcneely tripmcneely 1 month ago
100% go look at RVVTF which he pumped incessantly as it tanked
👍️ 1 💯 1
jimr1717 jimr1717 2 months ago
If EGOmike is pumping you better be dumping.

No one has pumped on more no bid stocks than the Ego.
👍️ 1
Retire43 Retire43 2 months ago
Please read and share this

https://medicaldialogues.in/medicine/news/galectin-3-promising-biomarker-for-predicting-long-covid-among-patients-of-covid-19-study-129158
👍️0
govprs govprs 2 months ago
Yes I believe you are correct
👍️0
Retire43 Retire43 2 months ago
Share this good news with everyone you know!

https://www.insiderfinancial.com/post/playing-the-bird-flu-trade-cvac-bixt-nnvc-govx-dyai-nvax
👍️0
Ecomike Ecomike 2 months ago
The first description of avian influenza (AI) dates back to 1878 in northern Italy, when Perroncito [Perroncito E. Epizoozia tifoide nei gallinacei. Annali Accad Agri Torino 1878;21:87-126] described a contagious disease of poultry associated with high mortality.
💩 1 🤡 1
cashmagnet cashmagnet 2 months ago
The vaccine wasn't created for the bird flu...The bird flu was created for the vaccine. So let's keep everyone sick. After all, from Merck's point of view, heal a patient\lose a customer...The disease management system we're saddled with has made the United States' pharmaceutical labyrinth the laughing stock of the civilized world during the past forty years. Pity...
👍️0
cashmagnet cashmagnet 2 months ago
The vaccine wasn't created for the bird flu; the bird flu was created for the vaccine....Heal a patient, lose a customer...I think that pretty much explains what's wrong with the disease management system that's made the U.S. the laughing stock of the civilized world during the past 40 years...
👍️ 1 💯 1
Ecomike Ecomike 2 months ago
BIXT CTB Cost To Borrow is already over 78% annual interest rate, up over 30000% above normal.

Shorts on BIXT got played..

Folks you have a choice. Bill Gate's Death by clot shot, if the Bird Flu vaccine or enhanced, Added gain of function, new improved bird flu, Bird flu a la Bill Gates research lab leaks the newer more dangerous bird flu they created for vaccine research....

Or BIXT, who has a published patent covering/targeting the galectin fold of 60+ viruses including bird flu and RSV, HIV, Epstein Barr's trigger MS, and Covid(all strains) and long haul covid19 with a non toxic oral pill, that has zero side effects?

Hard choice I know...

Is Big Pharma afraid of losing trillions of dollars of sales when BIXT gets approved and succeeds? 100% paranoid yes. So much so they have shorted the hell out of BIXT...

This is us, verses Big Pharama and their investors now

They will loose...

https://childrenshealthdefense.org/defender/united-states-bankrolling-creation-deadlier-contagious-bird-flu-strains/?utm_source=luminate&utm_medium=email&utm_campaign=defender&utm_id=20240520

💩 1 🤡 1
cashmagnet cashmagnet 2 months ago
YES!!!!
👍️0
Ecomike Ecomike 2 months ago
Dumb Money's (The Movie) Game Stop savior ROARING-KITTY that Bankrupted Ken Griffins 6.8 billions dollar hedge fund in 2021 is back today, after an 18 month break.
That stock and Amc rallied biggly today, So maybe we recuit them to get eyes on BIXT?
👍️0
cashmagnet cashmagnet 2 months ago
I agree that the National Institutes of Health and\or the US Military would be very useful collaborators in any attempt to establish a viable market for BIXT's biotech...But would either of them be willing to take a flier on a bulletin board company with no revenues? I certainly hope so, but...
👍️0
govprs govprs 2 months ago
Why not work with NIH?
👍️0
cashmagnet cashmagnet 2 months ago
It is indeed an ethical (and a preemptive) project that should be undertaken by anyone interested in avoiding the pain and extraordinary expense of current medical treatments typically prescribed for the very conditions Bioxytran appears equipped to address...That expressed, I'm nervous that Bioxytran may remain on the sidelines indefinitely unless the right kind (and number) of private (and retail) investors come forward to invest.

As always, we'll see...
C
👍️0
Ecomike Ecomike 2 months ago
That is why I call BIXT an ethical Investment in our health, that we the people need to fight for.
🍀 1 👑 1 💥 1 💩 1 💯 1 🤡 1
cashmagnet cashmagnet 2 months ago
It should have occurred to me that entrenched sector giants like Merck or J & J would prefer to squelch competition in the interest of ramping up profits, and would rather see BIXT remain an obscure, off-the-radar OTC company that can never threaten market share currently monoploized by the behemoths...Sigh...
👍️0
Retire43 Retire43 2 months ago
Todays emerging growth conference
CEO DAVID PLATT $BIXT
BioxyTran.

https://emerginggrowth.com/emerging-growth-conference-70/

👍️0
janga janga 2 months ago
Looks likes BIXT is the perfect remedy for a biological warfare just drop one of those pills
👍️ 1 💥 1 💯 1 🚀 1 🫡 1
Ecomike Ecomike 2 months ago
Only two problems, that will be solved. One is Hedge fund mugllers doing what they do. In our case handing us truck loads of gift priced shares from dumb (hedge fund) money.

The bigger they are, the harder they fall.

The other problem is that Big drug firms depend on lifelong sick people for their profits. They have no interesting in funding tech that will gut Cancer, and chronic autoimmune disease drug sales, that big pharma makes crime level profits off of.

This is where retail and ethical investors like us need to wake up and fund it, move it to warp speed, as fast as possible, because the health of friends and family and fellow humans now and in the future need it badly, asap.
🍀 1 👍️ 1 💎 1 💩 1 🤡 1
cashmagnet cashmagnet 3 months ago
It puzzles and dismays me that a patient-friendly non injectable remedy for common metabolic disorders hasn't yet attracted funding or transformed Bioxytran into a viable takeover target by, say, Merck, Monsanto or J&J, et al...I'm long on BIXT and will empty the bank for it if other stocks I'm waiting on come through in a timely manner...
👍️ 1
Ecomike Ecomike 3 months ago
$BIXT News analyst paper
https://www.nasdaq.com/press-release/6-stocks-positioned-to-soar-as-investors-focus-on-mash-2024-04-22

For those in a rush, slow readers, skip down the bottom for $BIXT connect the dots, connection.

Investing requires leading with an edge and some forethought. This article highlights pure-play drug developers in MASH likely to be the focus of investors looking for the next big thing in biotech.

Looking Beyond GLP-1 Inhibitors Toward the MASH Epidemic

Drug makers like Eli Lilly (NYSE: LLY) with their drug Mounjaro (tirzepatide) have already repurposed their drug once and are looking beyond diabetes and obesity, with their eyes set on and an even more lucrative market of metabolic dysfunction-associated steatohepatitis (MASH). LLY has promising interim clinical data showing 74% of overweight adults who took the higher dose of tirzepatide cleared MASH versus 12.6% in placebo. The first approval of a MASH drug on March 15, 2024 by Madrigal Pharmaceuticals (NASDAQ: MDGL) has ignited the sector with investors looking for the next big pure play.

Multiple MASH Targets

Metabolic dysfunction-associated steatohepatitis (MASH) is a complicated disease on the regulatory front. Approval criteria are a resolution of MASH symptoms via biopsy without a worsening of fibrosis. The disease formerly known as nonalcoholic steatohepatitis (NASH) is caused by a buildup of fat in the liver that leads to complications which include fibrosis (scarring of the liver), cirrhosis (severe scarring of the liver), and liver cancer. Once MASH progresses this far, liver transplantation is currently the only viable option. After MDGL’s approval of Rezdiffera®, investors have been flocking to other MASH names looking for a follow-on drug that either works in combination with Rezdiffera or one that is superior in safety and efficacy.

MASH Drug Targets

MASH has several druggable targets. The GLP-1 target is the mainstream approach because it also treats type 2 diabetes. Next in terms of a drug target is the fibroblast growth factor 21 (FGF21) which has a number of players in late-stage development. Galectin-3 is another target for MASH drugs as research has shown it is implicated in fibrotic and inflammatory feedback loops. There are also promising drugs that target the thyroid hormone receptor beta (THRß). Breaking from the mainstream approaches is the A3 adenosine receptor (A3AR) which is highly expressed in inflammatory and cancer cells whereas low expression is found in normal body cells.

FGF21 Agonists

89Bio Inc. (NASDAQ: ETNB) is developing a lead molecule called pegozafermin which is a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21). It is similar in mechanism of action to Bristol Myers Squibb’s (NYSE: BMY) drug pegbelfermin which was discontinued despite positive results which showed more than half the patients having NASH resolution at 16 weeks. FGF21 analogues are taken via subcutaneous injection. The targeting of the FGF21 pathway helps regulate metabolism and cellular process, especially in the liver fat tissue. Balancing out this metabolic pathway helps reduce liver fat, which can result in reduction in liver fibrosis (scarring) over time. The company has strong fibrosis data with favorable tolerability and dosing convenience. The long term data suggests there is a cumulative impact on patients taking background GLP-1 therapy. ETNB’s phase 3 program in MASH could achieve accelerated approval using histology in non-cirrhotic (F2-F3) and cirrhotic (F4) patients although the FDA has acknowledged greater importance in clinical outcomes and not histology. They have clinical trials in both fibrosis and cirrhosis and expect to initiate their cirrhosis trial in Q2 2024. The company has almost $600 million in cash with a market cap of $875 million. The slight premium over cash, solid and consistent trial results, along with short and long-term catalysts make this an attractive setup for investors. This is the first on the top 6 list.

Akero Therapeutics (NASDAQ: AKRO) is also targeting MASH and MASH cirrhosis with an FGF21 agonist. Their drug is called efruxifermin and is commonly referred to as EFX. In their phase 2b MASH trial they showed a 65% reduction in liver fat content vs 11% in placebo which places them close to the front of the pack because it was done in only 12 weeks. Unfortunately, their phase 2b trial in MASH missed the endpoint for improvement in liver fibrosis at the 12-week time frame but showed 60% had MASH resolution after 36 weeks versus 26% in placebo. The company lost a lot of value on that readout but the statistics show a cleanly designed trial is likely to hit the regulatory endpoints. Guidance from an end-of-trial FDA meeting is forthcoming, but the timing is still uncertain and weighing on the stock price. While there is a lot of potential in this name, the uncertain timing of the regulatory pathway makes this ideal for the patient investor looking more for a NASH cirrhosis play. The company is well funded with over $550 million in cash and a $1.5 billion market cap.

Galectin-3 Antagonists

Galectin Therapeutics (NASDAQ: GALT) has an adaptive design phase 2/3 study in NASH cirrhosis with an interim readout before year end 2024. Their intravenously administered galectin antagonist called belapectin showed complete prevention of esophageal varices in a phase 2 trial despite failing to meet their (now defunct) primary endpoints. Their pivotal trial used lessons learned from the phase 2 trial, utilizing a primary endpoint of prevention of esophageal varices. If the interim results confirm a complete or near complete prevention of varices like they did in their phase 2 trial, they would have a compelling argument for conditional approval, likely with another post-market confirmatory phase 3 trial. Almost 50% of patients that develop esophageal varices die within a year, and the varices are extremely costly to treat. So eliminating the significant and imminent threat of death is the compelling benefit.

The company is in solid financial shape with enough cash runway to complete their pivotal trial by 2025. They also have the backing of a billionaire investor who is also their Chairman of the Board. Additionally, their drug demonstrated promising results in cancer, psoriasis, and atopic dermatitis which could lead to a label expansion once they are approved. The market cap of the company is sitting around $225 million despite the near certainty of a positive interim trial readout within the next 8 months, which could translate into billions within that time frame.

The company is not alone in the space and has 2 other competitors with oral galectin-3 antagonists. Galecto Bioscience (NASDAQ: GLTO) announced they were scrapping their cancer drug, which had a 60% response rate after three months, to focus on NASH. GLTO had a failed trial in idiopathic pulmonary fibrosis because of their drug’s poor tolerability, which has forced them to seek strategic alternatives with a focus on liver disease. As a result, their development timelines for MASH are in flux. Galecto’s small molecule approach to inhibiting intracellular galectin-3 is the likely culprit for their drug’s poor tolerability and its more likely large molecules which target extracellular galectin-3 will succeed.

Bioxytran Inc. (OTCMKTS: BIXT) has the most technologically advanced oral galectin antagonist that completed phase 2 trials in standard risk COVID-19, but the company is underfunded and therefore moving forward cautiously. Both Bioxytran and Galectin Therapeutics are developing larger molecules compared with Galecto and both their drugs have been found to be safe as opposed to Galecto. Bioxytran’s additional benefit is that their drug doesn’t require intravenous administration. Their clinical trials in NASH or cancer are dependent upon them finding a partner or a couple million dollars to get a shot at a number of multibillion dollar opportunities. Management indicated that the quickest way to approval was a COVID-19 regulatory approval and then proceeding with the label expansion. While the company boasts impressive technology and experienced management, they don’t have the resources to prove their technology for all these indications yet. It's for these reasons that the stock should remain high on peoples watch lists—in case they get funding.

See the article for the rest of the story
💩 1 🤡 1
Retire43 Retire43 3 months ago
Please read this.

https://www.nasdaq.com/press-release/6-stocks-positioned-to-soar-as-investors-focus-on-mash-2024-04-22
👍️0
Zardiw Zardiw 3 months ago
Great Idea........one day $BIXT will be famous for curing these viruses..........

Z
👍️0

Your Recent History

Delayed Upgrade Clock